Steigerwalt Robert D, Belcaro Gianni, Morazzoni Paolo, Bombardelli Ezio, Burki Carolina, Schönlau Frank
Department of Biomedical Sciences, University of Chieti-Pescara, San Valentino, Italy.
Clin Ophthalmol. 2010 May 14;4:471-6. doi: 10.2147/opth.s9899.
The dietary supplement Mirtogenol((R)) was previously shown to lower elevated intraocular pressure (IOP). We here present the effects of this supplement on IOP in comparison as well as in combination with latanoprost eye drops.
Seventy-nine patients with asymptomatic ocular hypertension were randomly assigned to three groups receiving either the supplement, or latanoprost eye drops, or both in combination. Intraocular pressure and retinal blood flow were investigated in monthly intervals over 24 weeks.
Mirtogenol alone lowered IOP from baseline 38.1 to 29.0 mmHg after 16 weeks, with little further improvement during the following eight weeks. Latanoprost rapidly lowered IOP from baseline 37.7 to 27.2 mmHg within four weeks, without further effects thereafter. The combination of the supplement and latanoprost lowered IOP from 38.0 to 27.3 mmHg after four weeks, and further decreased IOP to 24.2 mmHg after six weeks. After 24 weeks IOP with the combination treatment (23.0 mmHg) was significantly lower than with latanoprost alone (27.2 mmHg). Mirtogenol and latanoprost individually showed comparable effects for gradually increasing central artery blood flow with treatment duration. Combination treatment showed higher systolic blood flow velocity throughout the trial period. The diastolic blood flow velocity gradually increased with treatment duration in all three groups. From twelve weeks onwards, the diastolic component with combination treatment was higher than with individual treatments.
Mirtogenol lowered elevated IOP in patients almost as effectively as latanoprost, however, it takes much longer (24 vs 4 weeks). The combination of both was more effective for lowering IOP and the combination yielded better retinal blood flow. No serious side effects occurred during the study, apart from standard side effects in patients related to Latanoprost. These promising results warrant further research of Mirtogenol with a larger patient group.
膳食补充剂米托蒽醌（Mirtogenol((R))）此前已被证明可降低升高的眼压（IOP）。我们在此展示该补充剂与拉坦前列素滴眼液相比以及联合使用时对眼压的影响。
79例无症状性高眼压患者被随机分为三组，分别接受该补充剂、拉坦前列素滴眼液或两者联合治疗。在24周内每月间隔测量眼压和视网膜血流。
单独使用米托蒽醌16周后眼压从基线38.1 mmHg降至29.0 mmHg，在随后的八周内几乎没有进一步改善。拉坦前列素在四周内迅速将眼压从基线37.7 mmHg降至27.2 mmHg，此后无进一步作用。补充剂与拉坦前列素联合使用四周后眼压从38.0 mmHg降至27.3 mmHg，六周后进一步降至24.2 mmHg。24周后联合治疗组的眼压（23.0 mmHg）显著低于单独使用拉坦前列素组（27.2 mmHg）。米托蒽醌和拉坦前列素在治疗过程中对逐渐增加中央动脉血流的作用相当。联合治疗在整个试验期显示出更高的收缩期血流速度。三组的舒张期血流速度均随治疗时间逐渐增加。从12周起，联合治疗组的舒张期成分高于单独治疗组。
米托蒽醌降低患者升高的眼压几乎与拉坦前列素一样有效，然而，所需时间要长得多（24周对4周）。两者联合使用在降低眼压方面更有效，且联合治疗产生更好的视网膜血流。除了与拉坦前列素相关的标准副作用外，研究期间未发生严重副作用。这些有前景的结果值得对更大患者群体进行米托蒽醌的进一步研究。
